Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123670182 | 12367018 | 2 | F | 20071002 | 20160801 | 20160513 | 20160812 | EXP | US-BAYER-2016-087601 | BAYER | 52.00 | YR | A | F | Y | 0.00000 | 20160812 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123670182 | 12367018 | 1 | PS | BETASERON | INTERFERON BETA-1B | 1 | Subcutaneous | 8 MIU, QOD | Y | 103471 | 8 | MIU | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | |||||
123670182 | 12367018 | 2 | SS | BETASERON | INTERFERON BETA-1B | 1 | Subcutaneous | 0.3 MG, QOD | Y | 103471 | .3 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | |||||
123670182 | 12367018 | 3 | C | CALCIUM | CALCIUM | 1 | Oral | UNK, BID | 0 | BID | |||||||||
123670182 | 12367018 | 4 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | UNK, BID | 0 | BID | |||||||||
123670182 | 12367018 | 5 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | UNK, 4IW | 0 | ||||||||||
123670182 | 12367018 | 6 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | 4 DF, OW | 0 | 4 | DF | /wk | |||||||
123670182 | 12367018 | 7 | C | NEURONTIN | GABAPENTIN | 1 | Oral | 1 DF, TID | 0 | 1 | DF | TID | |||||||
123670182 | 12367018 | 8 | C | PROZAC | FLUOXETINE HYDROCHLORIDE | 1 | Oral | UNK, HS | 0 | QD | |||||||||
123670182 | 12367018 | 9 | C | PROZAC | FLUOXETINE HYDROCHLORIDE | 1 | Oral | 1 DF, QHS | 0 | 1 | DF | ||||||||
123670182 | 12367018 | 10 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Nasal | UNK, 160/4.5 BID | 0 | BID | |||||||||
123670182 | 12367018 | 11 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Oral | 150 MG, ADD'L SIG ADD'L SIG BY MOUTH | 0 | 150 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
123670182 | 12367018 | 1 | Multiple sclerosis |
123670182 | 12367018 | 2 | Multiple sclerosis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
123670182 | 12367018 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
123670182 | 12367018 | Arthralgia | |
123670182 | 12367018 | Ataxia | |
123670182 | 12367018 | Chest discomfort | |
123670182 | 12367018 | Choking | |
123670182 | 12367018 | Dysmetria | |
123670182 | 12367018 | Dysphagia | |
123670182 | 12367018 | Facial pain | |
123670182 | 12367018 | Fatigue | |
123670182 | 12367018 | Hyperreflexia | |
123670182 | 12367018 | Initial insomnia | |
123670182 | 12367018 | Middle insomnia | |
123670182 | 12367018 | Multiple sclerosis | |
123670182 | 12367018 | Multiple sclerosis relapse | |
123670182 | 12367018 | Muscular weakness | |
123670182 | 12367018 | Musculoskeletal disorder | |
123670182 | 12367018 | Neck pain | |
123670182 | 12367018 | Nystagmus | |
123670182 | 12367018 | Oesophageal spasm | |
123670182 | 12367018 | Osteoarthritis | |
123670182 | 12367018 | Pain | |
123670182 | 12367018 | Pain in extremity | |
123670182 | 12367018 | Paraesthesia | |
123670182 | 12367018 | Rheumatoid arthritis | |
123670182 | 12367018 | Rheumatoid factor increased | |
123670182 | 12367018 | Sensory level | |
123670182 | 12367018 | Spinal osteoarthritis | |
123670182 | 12367018 | Spondylolysis | |
123670182 | 12367018 | Tremor |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
123670182 | 12367018 | 1 | 20071019 | 20150201 | 0 |